DATABASE
SYS.ONLINE
🔒 SECURE
Nootropic ● Verified

Dihexa

Angiotensin IV analogue, investigated for its extremely potent neurogenic capacity.
Half-Life
Unknown
Onset
Slow (Days)
Duration
Sustained
Route
Oral
Mechanism of Action

Angiotensin IV analogue. Potentiates HGF/c-Met signalling, inducing massive synaptogenesis and dendritic spinogenesis.

Key Benefits
  • Formation of new synapses (Neurogenesis)
  • Cognitive recovery (Alzheimer's/Parkinson's models)
  • Higher potency than BDNF (research)
  • Improved memoryFormation of new synapses (Neurogenesis)
  • Memory improvement
Evidence Notes
RESEARCH RANGE (Non-prescriptive): Studied in doses of 10mg to 20mg. Level of Evidence: C (Pre-clinical).
Risk Profile
  • Theoretical risk of oncogenesis (activation of growth factors).
Overview

Dihexa is an oligopeptide derived from Angiotensin IV with a unique ability to cross the blood-brain barrier and promote synaptogenesis through the activation of hepatocyte growth factor (HGF).

READ MORE

What it is (in plain language)
- It is one of the most powerful nootropics known. While others merely 'stimulate' the brain, Dihexa helps to create new connections (synapses) between neurons. It was originally developed to reverse damage in diseases such as Alzheimer's, focussing on repairing the brain's infrastructure.

Why do you appear online so much
- It is often described as an industrial-grade 'mental fog cleaner'. Biohackers use it to increase mental processing speed and long-term memory, although it is an extremely powerful substance that requires caution.

How it is framed today (pragmatic view)
- 1) Evidence: Extraordinary pre-clinical results in neurodegeneration models. 2) Objective: Cognitive rehabilitation and extreme neuroplasticity. 3) Risk: As it promotes cell growth via HGF, it should be avoided by anyone with an oncological risk.

How to use this form
- Read the safety section on activating the c-Met receiver carefully.

- Quick profile (curated by Subject 157)
- Class: Nootropic
- Status: Verified
- Use case: Nootropic
- Route: Oral
- Tags: Oral|Transdermal|Brain
- Half-life: Unknown
- Start: Slow (Days)
- Duration: Sustained

- Mechanism (high level)
Angiotensin IV analogue. Potentiates HGF/c-Met signalling, inducing massive synaptogenesis and dendritic spinogenesis.

- Evidence (what the literature covers)
RESEARCH RANGE (Non-prescriptive):
Studied in doses of 10mg to 20mg.
Level of Evidence: C (Pre-clinical).

- Safety and harm-reduction (non-prescriptive)
Risks: Theoretical risk of oncogenesis (activation of growth factors).
Interactions: Unknown.

- References (anchors)
- Benoist, C. C. (2011) - Dihexa facilitates synaptogenesis and memory - https://doi.org/10.1124/jpet.111.182220 | PubMed:21990598
- Nguyen, L. (2021) - AngIV-analog dihexa and cognitive protection review - https://doi.org/10.3390/brainsci11111487 | PubMed:34827486

Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.

Scientific References
Benoist, C. C. (2011) - Dihexa facilitates synaptogenesis and memory -
Nguyen, L. (2021) - AngIV-analog dihexa and cognitive protection review - C. C. (2011) - Dihexa facilitates synaptogenesis and memory -
Nguyen, L. (2021) - AngIV-analog dihexa and cognitive protection review -
/// RECONSTITUTION
0
Insulin Units (IU)
🧪
LAB TOOLS
Access full suite for COA audit.
OPEN SUITE
Snapshot
Use CaseNootropic
AliasesPNB-0408
StorageAmbient temperature.
HandlingKeep dry.
Interactions
Unknown.
en_GBEN